Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $28.98 USD
Change Today +0.44 / 1.54%
Volume 122.1K
DNAI On Other Exchanges
Symbol
Exchange
Frankfurt
As of 2:28 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

pronai therapeutics inc (DNAI) Snapshot

Open
$29.05
Previous Close
$28.54
Day High
$29.37
Day Low
$27.50
52 Week High
07/16/15 - $33.75
52 Week Low
07/27/15 - $25.16
Market Cap
835.5M
Average Volume 10 Days
314.3K
EPS TTM
--
Shares Outstanding
28.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRONAI THERAPEUTICS INC (DNAI)

Related News

No related news articles were found.

pronai therapeutics inc (DNAI) Related Businessweek News

No Related Businessweek News Found

pronai therapeutics inc (DNAI) Details

ProNAi Therapeutics, Inc., a clinical-stage oncology company, develops and commercializes a class of therapeutics based on its DNA interference (DNAi) technology platform. Its lead DNAi product candidate is PNT2258, a single-stranded 24-base DNAi oligonucleotide, which targets BCL2, an oncogene that is an important gatekeeper of the programmed cell death process known as apoptosis and has been linked to many forms of cancer. The company was formerly known as Phenome Systems, Inc. and changed its name to ProNAi Therapeutics, Inc. in April 2004. ProNAi Therapeutics, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

27 Employees
Last Reported Date: 07/16/15
Founded in 2003

pronai therapeutics inc (DNAI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Chief Scientific Officer and Vice President o...
Total Annual Compensation: --
Chief Medical Officer
Total Annual Compensation: --
Chief Business and Strategy Officer and Head ...
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

pronai therapeutics inc (DNAI) Key Developments

ProNAi Therapeutics Inc. Appoints Dr. Barbara Klencke as Chief Development Officer

ProNAi Therapeutics Inc. announced that it has appointed Dr. Barbara Klencke, M.D., as Chief Development Officer. Dr. Klencke is an accomplished oncology drug developer with a demonstrable track record of success, having made substantial contributions to the development and approval of numerous significant oncology products, including Kyprolis, Kadcyla, Avastin and Tarceva. Previously, Dr. Klencke served as the Senior Vice President, Development at Onyx Pharmaceuticals.

ProNAi Therapeutics Appoints Nicole Onetto and Robert Pelzer to the Board of Directors

ProNAi Therapeutics appointed Dr. Nicole Onetto, M.D. and Mr. Robert Pelzer, LLB to its Board of Directors. Dr. Nicole Onetto, M.D. has served as the Deputy Director and Chief Scientific Officer at the Ontario Institute for Cancer Research since November 2009. Dr. Onetto previously served as the Senior Vice President and Chief Medical Officer at ZymoGenetics, Inc. Dr. Onetto currently serves on the board of directors of ImmunoGen, Inc. Mr. Robert Pelzer served as the President of Novartis Corporation from September 2008 to March 2013, and was responsible for the Novartis Group Companies in the United States. Mr. Pelzer currently serves on the board of directors of Aquinox Pharmaceuticals, Inc. and Qu Biologics Inc.

ProNAi Therapeutics Inc. Announces Executive Appointments; Opens Corporate Headquarters in Vancouver, British Columbia, Canada

ProNAi Therapeutics Inc. announced that it has further strengthened its management team with the addition of three experienced senior executives. Joining the company are Sukhi Jagpal, CA, CBV, MBA, Chief Financial Officer, Simon Eastman, Ph.D., Vice President of Global Manufacturing and Technical Operations and Diane Gardiner, Vice President of Human Resources. Sukhi Jagpal joins the company as Chief Financial Officer (CFO). Previously, Sukhi was the CFO of QLT Inc. During his tenure, he assisted QLT in developing its finance capabilities to deal with several growth phases, which included raising capital and completing several acquisitions. Dr. Simon Eastman joins the company as Vice President, Global Manufacturing and Technical Operations. Dr. Eastman has more than 25 years of experience in research, development and manufacturing of lipid nanoparticle (LNP) formulations. Over the past twelve years, Dr. Eastman was Director of Research and Development at Northern Lipids. Diane Gardiner joins the company as Vice President of Human Resources. Ms. Gardiner is an accomplished Human Resources professional with more than 20 years of experience in the life sciences sector. Prior to joining the company, Diane served as Vice President of Human Resources for Tekmira Pharmaceuticals. Before joining Tekmira, she held the positions of Head of Human Resources for Aquinox Pharmaceuticals, Vice President of Human Resources for The Centre for Drug Research and Development, and Director of Human Resources for AnorMED Inc. The company also announced that it has opened its corporate headquarters in Vancouver, located at 2150 - 885 West Georgia Street, Vancouver, British Columbia, Canada, V6C 3E8. The company continues to maintain research operations in Plymouth, Michigan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DNAI:US $28.98 USD +0.44

DNAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DNAI.
View Industry Companies
 

Industry Analysis

DNAI

Industry Average

Valuation DNAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 21.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRONAI THERAPEUTICS INC, please visit www.pronai.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.